Fundz
Real-time · AI · Cross-signal

Boehringer Ingelheim just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Boehringer Ingelheim, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
▶
Watch the 2-minute tour · with sound

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration for Precision Cancer Treatment

Oct 09, 2024•over 1 year ago

Contract Type

partnership

Ingelheim am RheinPharmaceuticalpharmaceuticals

Description

Boehringer Ingelheim and Circle Pharma have announced a new research collaboration and license agreement aimed at developing a first-in-class cyclin inhibitor to halt the growth of cancer cells. The collaboration focuses on targeting proteins involved in cell division regulation, offering hope for those with hard-to-treat cancers.

Company Information

Company

Boehringer Ingelheim

Location

173 Binger Strasse

Ingelheim am Rhein, Rhineland-Palatinate, Germany

About

Boehringer Ingelheim International GmbH is a multinational pharmaceutical company that has transferred the rights of three anti-diabetes trademarks—Gibtulio, Gibtulio Met, and Ajaduo—to Lupin Limited.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Boehringer Ingelheim's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months